rivaroxaban
Xarelto (rivaroxaban) is an oral factor Xa inhibitor from Bayer that blocks a key enzyme of the clotting cascade. It prevents and treats deep vein thrombosis and pulmonary embolism, reduces stroke risk in atrial fibrillation, and lowers cardiovascular events after acute coronary syndromes or in coronary and peripheral artery disease.
This page is based on FDA prescribing information and the EMA medicine record for rivaroxaban, cross-checked with MedlinePlus and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Blood clotting runs along a relay, and factor Xa is the runner that hands off the baton to thrombin, which builds the clot. Rivaroxaban takes that runner out of the race. Whether the clot threat comes from an immobile leg, a faulty heart rhythm, or a stented artery, the relay cannot finish, and dangerous clots are far less likely to form.
In simple terms
Rivaroxaban is taken by mouth and belongs to the factor Xa inhibitor class. It selectively blocks factor Xa, an enzyme the body needs to turn prothrombin into thrombin during clot formation. With less thrombin generated, fewer fibrin clots form. This is why rivaroxaban can treat and prevent clots in the legs and lungs, reduce stroke risk in people with certain irregular heart rhythms, and lower the chance of heart attack or stroke in people with coronary or peripheral artery disease.
In depth
Rivaroxaban is an orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration it selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex, interfering with the conversion of prothrombin (factor II) to thrombin and eventually preventing the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels, which preserves haemostatic balance while reducing pathological thrombus formation across venous and arterial indications.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How rivaroxaban directly inhibits factor Xa
- Blood clotting runs along a relay, and factor Xa is the runner that hands off the baton to thrombin, which builds the clot.
- Rivaroxaban is an orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity.
- Upon oral administration it selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex, interfering with the conversion of prothrombin (factor II) to thrombin and eventually preventing the formation of cross-linked fibrin clots.
- Rivaroxaban does not affect existing thrombin levels, which preserves haemostatic balance while reducing pathological thrombus formation across venous and arterial indications.
Target: Coagulation factor Xa
The enzyme at the convergence of the clotting cascade that converts prothrombin to thrombin; blocking it prevents new fibrin clots from forming without affecting thrombin already present.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- In combination with aspirin, to reduce the risk of major cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in adult patients with coronary artery disease
- In combination with aspirin, to reduce the risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology) in adult patients with peripheral artery disease, including patients who have recently undergone a lower extremity revascularization procedure due to symptomatic peripheral artery disease
Approved uses in United States
FDA- To prevent and treat deep vein thrombosis (a blood clot) and pulmonary embolism (a blood clot in the lung)
- To lower the risk of a heart attack, stroke, or death in people with coronary artery disease or peripheral arterial disease
Approved uses in European Union
EMA- Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adults after an acute coronary syndrome with elevated cardiac biomarkers
- Co-administered with ASA, for the prevention of atherothrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease at high risk of ischaemic events
- For the prevention of venous thromboembolism in adults undergoing elective hip or knee replacement surgery
- For the treatment of deep vein thrombosis and pulmonary embolism, and prevention of recurrent deep vein thrombosis and pulmonary embolism, in adults
- For the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, or prior stroke or transient ischaemic attack
- For the treatment of venous thromboembolism and prevention of recurrence in children and adolescents under 18 years of age after at least five days of initial parenteral anticoagulation treatment
Official sources
The statements on this page trace back to these records.
- Xarelto (rivaroxaban) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: rivaroxaban prescribing information
U.S. Food and Drug Administration
- MedlinePlus: rivaroxaban
MedlinePlus, U.S. National Library of Medicine
- National Cancer Institute: rivaroxaban
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.